New classification for identifying HR myeloma based on cytogenetic abnormalities

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Assessment of suicide risk in cancer patients

Managing 'fear of recurrence' of cancer patients

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Haemopathy burden in the National Cancer Center of Cambodia